Quotes 5-day view Delayed Nyse
09/14/2020
09/15/2020
09/16/2020
09/17/2020
09/18/2020
Date
84.16(c)
84.21(c)
85.57(c)
85.64(c)
85.81(c)
Last
8 183 210
10 330 789
9 905 007
7 719 928
11 575 380
Volume
-0.38% +0.06% +1.62% +0.08% +0.20% Change
Sales 2020
47 947 M - -
Net income 2020
12 057 M - -
Net Debt 2020
15 643 M - -
P/E ratio 2020
18,1x
Yield 2020
2,82%
Sales 2021
51 388 M - -
Net income 2021
14 087 M - -
Net Debt 2021
13 088 M - -
P/E ratio 2021
15,6x
Yield 2021
3,04%
Capitalization
217 B 217 B -
EV / Sales 2020
4,85x
EV / Sales 2021
4,48x
Nbr of Employees
71 000
Free-Float
70,6%
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (72.1%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of...
Notations Surperformance© of Merck & Co., Inc.
Trading Rating : Investor Rating :
All news about MERCK & CO., INC.
News in other languages on MERCK & CO., INC.
Analyst Recommendations on MERCK & CO., INC.
MERCK AND COMPANY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MERCK & CO., INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
19
Average target price
96,06 $
Last Close Price
85,81 $
Spread / Highest target
24,7%
Spread / Average Target
11,9%
Spread / Lowest Target
-2,11%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
